[go: up one dir, main page]

JPH0827283B2 - Composition for immunoaggregation reaction - Google Patents

Composition for immunoaggregation reaction

Info

Publication number
JPH0827283B2
JPH0827283B2 JP61052890A JP5289086A JPH0827283B2 JP H0827283 B2 JPH0827283 B2 JP H0827283B2 JP 61052890 A JP61052890 A JP 61052890A JP 5289086 A JP5289086 A JP 5289086A JP H0827283 B2 JPH0827283 B2 JP H0827283B2
Authority
JP
Japan
Prior art keywords
sensitized
carrier
freeze
stabilizer
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61052890A
Other languages
Japanese (ja)
Other versions
JPS62209362A (en
Inventor
春雄 藤田
一右 工藤
正憲 宇野木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO
Original Assignee
KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO filed Critical KAGAKU OYOBI KETSUSEI RYOHO KENKYUSHO
Priority to JP61052890A priority Critical patent/JPH0827283B2/en
Publication of JPS62209362A publication Critical patent/JPS62209362A/en
Publication of JPH0827283B2 publication Critical patent/JPH0827283B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

【発明の詳細な説明】 本発明は間接担体凝集反応、凝集抑制反応等の抗原−
抗体凝集反応に用いる、抗原(または抗体)感作担体を
含む水性組成物、特に長期間にわたり安定的に使用でき
るように改良されたそのような組成物に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to antigens such as indirect carrier agglutination reaction and aggregation suppression reaction.
It relates to an aqueous composition containing an antigen (or antibody) -sensitized carrier for use in an antibody agglutination reaction, in particular, such a composition improved for stable use over a long period of time.

検体中の抗原または抗体の測定を、対応する抗体また
は抗原を感作した感作担体と検体との凝集反応によって
行う、いわゆる間接担体凝集反応はすでに確立されてい
る方法である。
The so-called indirect carrier agglutination reaction, in which the antigen or antibody in the sample is measured by the agglutination reaction between the sensitized carrier sensitized with the corresponding antibody or antigen and the sample, is a method already established.

この方法は、操作が簡便で、判定が容易、短時間で判
定可能、比較的高感度、再現性が高い、経費が少なくて
済む、特別な機器がが不要でどこでも手軽に実施でき
る、などの種々の利点により広く一般に利用されてい
る。
This method is easy to operate, easy to judge, can be judged in a short time, relatively high sensitivity, high reproducibility, low cost, no special equipment is required, and it can be performed easily anywhere. It is widely used due to its various advantages.

一般に、抗原または抗体を感作させる担体としては、
哺乳類または鳥類由来の固定または固定しない赤血球、
あるいはラテックス、スチレン重合体、ゼラチン、エポ
キシ樹脂、セルロース樹脂、活性炭末などの人工担体が
用いられる。赤血球の固定は、一般に、ホルムアルデヒ
ド、グルタルアルデヒド、ピルビンアルデヒド等のアル
デヒド類で行われ、その保存性を高めるためである。こ
れらの担体に抗原あるいは抗体を感作した感作担体の水
性浮遊液は、一応の保存安定性を有し、およそ2〜3ヶ
月は使用可能である。しかしながら、感作担体を工業的
に製造するためには、1年以上の保存安定性が要求され
ている。
Generally, as a carrier for sensitizing an antigen or antibody,
Fixed or non-fixed red blood cells from mammals or birds,
Alternatively, artificial carriers such as latex, styrene polymer, gelatin, epoxy resin, cellulose resin and activated carbon powder are used. This is because the fixation of red blood cells is generally performed with aldehydes such as formaldehyde, glutaraldehyde, pyruvaldehyde, etc., to improve their storage stability. An aqueous suspension of a sensitized carrier prepared by sensitizing these carriers with an antigen or an antibody has tentative storage stability and can be used for about 2 to 3 months. However, in order to industrially manufacture the sensitized carrier, storage stability of one year or more is required.

そこで、感作担体の水性浮遊液を凍結乾燥し、更に保
存安定性を延ばそうという試みがなされている。しかし
ながら、水性浮遊液の状態で凍結乾燥を行うと、凍結乾
燥しないものと比べて凍結乾燥後は、外見の形状の悪化
(縮まった状態、カルメラ状etc)、反応パターンの悪
化、保存安定性が良くない、再現性が悪い等の問題が生
ずる。これは明らかに凍結乾燥工程が感作担体に悪影響
を与えるためと思われる。
Therefore, attempts have been made to freeze-dry an aqueous suspension of the sensitized carrier to further extend the storage stability. However, when freeze-drying is performed in the state of an aqueous suspension, deterioration of the appearance shape (shrinked state, carmel-like etc.), deterioration of reaction pattern, and storage stability after freeze-drying are less than those without freeze-drying. Problems such as poor quality and poor reproducibility occur. This is apparently because the freeze-drying process adversely affects the sensitized carrier.

従って、凍結乾燥を行わなくて済むか、あるいは凍結
乾燥しても凍結乾燥前後で反応パターンに変化がなく、
外見の形状も良く、更に1年以上安定的に使用できるよ
うな感作担体の浮遊液が要求されている。
Therefore, it is not necessary to freeze-dry, or even if freeze-drying, there is no change in the reaction pattern before and after freeze-drying,
There is a demand for a suspension of a sensitizing carrier which has a good appearance and can be used stably for more than one year.

本発明者らは、鋭意研究した結果、感作担体の水性浮
遊液即ち懸濁液に特定量の糖、さらに選択的にアルブミ
ンを存在させることによって、上記問題点を一挙に解決
しうることを見出し、本発明を完成するに至った。
As a result of intensive studies, the inventors of the present invention have found that the above problems can be solved all at once by allowing a specific amount of sugar and further selectively albumin to be present in an aqueous suspension or suspension of a sensitized carrier. Heading out, the present invention has been completed.

すなわち、本発明は、間接担体凝集反応、凝集抑制反
応等の抗原−抗体凝集反応に用いる感作担体の水性浮遊
液を製造する際に、感作担体の保存安定性を高める目的
で感作担体水性浮遊液中に特定の安定剤物質を特定量で
添加して改良された保存安定性の高い感作担体含有水性
組成物を提供することにある。
That is, the present invention provides a sensitized carrier for the purpose of enhancing the storage stability of the sensitized carrier when producing an aqueous suspension of the sensitized carrier used in an antigen-antibody agglutination reaction such as an indirect carrier agglutination reaction and an aggregation suppression reaction. A specific stabilizer substance is added to an aqueous suspension in a specific amount to provide an improved sensitized carrier-containing aqueous composition having high storage stability.

そのような特定量の特定の安定剤とは、2〜20W/V%
のラクトースである。このラクトースは、約2W/V%より
少ないと保存安定性を高める効果は弱く、20W/V%より
多いと外見が非常に悪くなる傾向があり、また、粘度の
増大あるいは溶解が困難となり、本発明の目的に適さな
い。特に好ましいラクトース濃度は、5〜10W/V%であ
る。
Such a specific amount of a specific stabilizer is 2 to 20 W / V%
Is lactose. If the amount of this lactose is less than about 2 W / V%, the effect of enhancing the storage stability is weak, and if it is more than 20 W / V%, the appearance tends to be very poor, and it becomes difficult to increase the viscosity or dissolve it. Not suitable for the purpose of the invention. A particularly preferred lactose concentration is 5-10 W / V%.

また、選択的に前記ラクトースにアルブミンを添加す
ることにより、ラクトース単味添加の場合と比べて、そ
の効果は更に増幅される。この増幅効果はラクトースと
アルブミンの好ましい濃度の組合せにおいて特に顕著で
ある。最も好ましいアルブミンの濃度は、5〜10W/V%
のラクトースに対して0.05〜1W/V%である。使用される
アルブミンは、ヒド、ウシ、ウマ、ヤギ、ヒツジ、ウサ
ギ、ニワトリ由来などのいずれを用いてもよいが、とり
わけ、ウシ又はヒトの血清アルブミンを使用することが
好都合である。
Also, by selectively adding albumin to the lactose, the effect is further amplified as compared with the case of adding lactose alone. This amplification effect is particularly pronounced in the preferred combination of lactose and albumin concentrations. The most preferred albumin concentration is 5-10 W / V%
It is 0.05-1 W / V% with respect to lactose. The albumin used may be any of those derived from hide, bovine, horse, goat, sheep, rabbit, chicken and the like, but it is particularly preferable to use bovine or human serum albumin.

感作担体を0.5〜10W/V%の割合に含有する水性浮遊液
に、上記の安定剤を添加しよく混和後、バイアルに分注
し、そのまま保存してもよいが、さらに好ましいのは、
このバイアルを、前もって−40〜−45℃程度に冷却して
おいた凍結乾燥機のチャンバー内の棚にいれ、24時間か
ら48時間にわたって真空凍結乾燥する。その後、真空状
態または窒素ガスを充填したのち封栓をして、凍結乾燥
担体ができあがる。
An aqueous suspension containing a sensitizing carrier in a proportion of 0.5 to 10 W / V%, after well mixed with the above stabilizer, and mixed well, may be dispensed into a vial and stored as it is, but more preferably,
This vial is put on a shelf in a chamber of a freeze dryer which has been cooled to about -40 to -45 ° C in advance, and vacuum freeze dried for 24 to 48 hours. After that, a freeze-dried carrier is completed by sealing in a vacuum or after filling with nitrogen gas.

凍結乾燥感作担体は、水または適当な希釈液を加えて
復元し、そのままの濃度で、あるいは必要に応じて希釈
により濃度を調整して、間接担体凝集反応等に用いるこ
とが出来る。
The freeze-dried sensitized carrier can be reconstituted by adding water or an appropriate diluent, and can be used for the indirect carrier agglutination reaction or the like by adjusting the concentration as it is or by adjusting the concentration by dilution if necessary.

本発明による安定剤を用いて凍結乾燥した感作担体
は、4℃保存2年間以上にわたって使用可能である。
The sensitized carrier freeze-dried using the stabilizer according to the present invention can be stored at 4 ° C. for 2 years or more.

本発明による安定剤の添加は、感作担体だけではな
く、固定血球を担体として使用した場合には担体そのも
のの保存安定性を高め得る。従って、本発明は担体とし
て血球を使用する場合に極めて有利に適用できる。ま
た、感作担体浮遊体に本発明による安定剤を添加したま
まの状態、即ち凍結乾燥を行わず液体状態のままで保存
した場合においても、感作担体は少なくとも4℃、6ヶ
月は充分安定的に使用可能であり、凍結乾燥による不都
合を避けなければならない用途には極めて有効である。
The addition of the stabilizer according to the present invention can enhance the storage stability of not only the sensitized carrier but also the carrier itself when fixed blood cells are used as the carrier. Therefore, the present invention can be applied extremely advantageously when blood cells are used as a carrier. Further, even when the stabilizer of the present invention is added to the sensitized carrier suspension in a liquid state without freeze-drying, the sensitized carrier is sufficiently stable at 4 ° C. for 6 months. It can be used for a long time and is extremely effective for applications where the disadvantages of freeze-drying must be avoided.

かくして、本発明によれば、優れた品質を長期間安定
的に保持することの出来る感作担体を工業的に生産する
ことが可能となり、病院や臨床検査センター等の日常の
臨床検査業務用として安価に供給できる。
Thus, according to the present invention, it becomes possible to industrially produce a sensitizing carrier capable of stably maintaining excellent quality for a long period of time, and for daily clinical laboratory work such as hospitals and clinical laboratory centers. Can be supplied at low cost.

担体に感作する物質としては、何らかの方法で担体に
感作できるものであれば全ての抗原性物質、抗体を対象
とできる。
As the substance to be sensitized to the carrier, any antigenic substance or antibody can be used as long as it can be sensitized to the carrier by some method.

また感作担体を浮遊させる溶液は、感作担体に悪影響
を及ぼさないものであればいかなるものでもよく、一般
的には生理食塩液、PBS(リン酸緩衝食塩液)などが使
用できる。
The solution for suspending the sensitized carrier may be any solution as long as it does not adversely affect the sensitized carrier, and physiological saline, PBS (phosphate buffered saline) or the like can be generally used.

以下、本発明を実施例によりさらに具体的に説明す
る。
Hereinafter, the present invention will be described more specifically by way of examples.

実施例 1 〔羊赤血球の固定〕 羊の血液を100ml採血し、オルセバ液100mlと混合し、
ガーゼ濾過し、ヘマトクリットによリ血球の濃度を測定
した。生理食塩液で5回洗浄し、その後“Methods in l
mmunology and lmmuno chemistry,vol.VI pp.33〜34 19
77年(WILLIAMS,CHASE編 Academic Press New York)”
のAbram B,Stavitskyの記載に従い、ホルマリン固定羊
血球を調製した。
Example 1 [Fixation of sheep red blood cells] 100 ml of sheep blood was collected and mixed with 100 ml of Orseva solution,
Gauze filtration was performed, and the concentration of blood cells was measured by hematocrit. Wash 5 times with physiological saline, then “Methods in l
mmunology and lmmuno chemistry, vol.VI pp.33〜34 19
77 years (WILLIAMS, CHASE, Academic Press New York) ”
Formalin-fixed sheep blood cells were prepared as described by Abram B, Stavitsky.

すなわち、洗浄遠心した赤血球の沈澱の8倍量の冷3V
/V%ホルムアルデヒド生理食塩液を加え4℃24時間ゆっ
くり撹はんする。さらにその2倍量の冷40V/V%ホルム
アルデヒド生理食塩液を加え24時間撹はんした。次い
で、赤血球をガーゼで濾過し、生理食塩液で8回洗浄
し、PBS(M/15リン酸緩衝食塩液pH7.2)で2.5V/V%にな
るように懸濁し、窒化ソーダ0.1W/%を加え4℃にて保
存した。
That is, 8 times the amount of cold 3V as the precipitate of erythrocytes washed and centrifuged.
Add / V% formaldehyde saline and stir slowly at 4 ° C for 24 hours. Furthermore, twice the amount of cold 40V / V% formaldehyde physiological saline was added and the mixture was stirred for 24 hours. Then, the red blood cells were filtered with gauze, washed with physiological saline eight times, and suspended with PBS (M / 15 phosphate buffered saline pH7.2) to a concentration of 2.5 V / V%, sodium nitride 0.1 W / % And added and stored at 4 ° C.

〔サイログロブリン感作担体の作製〕[Preparation of carrier for sensitizing thyroglobulin]

上記で調製した固定羊赤血球をさらにPBSで2回洗浄
し、PBS中赤血球濃度が2.5V/V%になるように懸濁し
た。“Methods in lmmunology and immunochemistry,vo
l.IV pp.36"(前出)を参考に、抗原を固定羊赤血球に
感作した。抗原としては生化学工業(株)より購入した
サイログロブリンを用いた。すなわち、タンニン酸をPB
Sで0.001W/V%に希釈し、600mlの2.5V/V%羊固定赤血球
と等量混合し、37℃45分反応させた。その後、PBSで3
回洗浄し、600mlのPBSに再懸濁した。このタンニン酸処
理赤血球600mlにサイログロブリンの50μg/mlPBS溶液60
0mlを加え、37℃30分感作した。PBSで3回洗浄したの
ち、0.1W/V%窒化ソーダを含むPBS1500mlで懸濁し間接
担体凝集反応用のサイログロブリン感作血球を1V/V%濃
度で1500ml得た。
The fixed sheep red blood cells prepared above were further washed twice with PBS and suspended so that the red blood cell concentration in PBS was 2.5 V / V%. “Methods in lmmunology and immunochemistry, vo
The antigen was sensitized to fixed sheep red blood cells with reference to l.IV pp.36 "(supra). Thyroglobulin purchased from Seikagaku Corporation was used as the antigen.
The mixture was diluted to 0.001 W / V% with S, mixed with 600 ml of 2.5 V / V% sheep fixed erythrocytes in an equal amount, and reacted at 37 ° C for 45 minutes. Then 3 with PBS
It was washed twice and resuspended in 600 ml PBS. To 600 ml of this tannic acid-treated red blood cell, 50 μg / ml PBS solution of thyroglobulin 60
0 ml was added and sensitization was performed at 37 ° C for 30 minutes. After washing 3 times with PBS, it was suspended in 1500 ml of PBS containing 0.1 W / V% sodium nitride to obtain 1500 ml of thyroglobulin-sensitized blood cells for indirect carrier aggregation reaction at a concentration of 1 V / V%.

〔凍結乾燥〕〔freeze drying〕

上で得たサイログロブリン感作血球1V/V%浮遊液に、
第1表の各安定剤を加えて、凍結乾燥用10mlバイアルに
2.5mlずつ分注し、前もって−45℃に冷却しておいた真
空凍結乾燥機のチャンバー内に入れ、−50℃で2時間、
−50℃〜+15℃で10時間、+20℃で12時間の温度推移で
凍結乾燥した。乾燥終了後バイアル内に窒素ガスを充填
したのち封栓した。かくして得られた凍結乾燥感作血球
の性状を比較した結果を第1表に示す。なお、乾燥後の
外見は縮んだ形態の程度で判定した。反応パターンは、
各々の凍結乾燥感作血球に水2.5mlを加えて1V/V%感作
血球浮遊液に復元したものを用いて、抗サイログロブリ
ン抗体陽性血清および陰性血清を検体として、常法に従
って間接担体(血球)凝集反応を行ったときの陽性パタ
ーン、陰性パターンより判定した。×と判定したもの
は、陰性パターンの陽性化がみられたものである。反応
パターンについては、その安定性を経時的に試験した。
その結果、第1表で有効性○としたサンプルは、保存安
定性が著しく向上したものである。
To the thyroglobulin-sensitized blood cell 1V / V% suspension obtained above,
Add each stabilizer in Table 1 to a 10 ml vial for lyophilization.
Dispense 2.5 ml aliquots into the chamber of the vacuum lyophilizer that had been previously cooled to -45 ° C, and then at -50 ° C for 2 hours,
Lyophilization was carried out at a temperature of −50 ° C. to + 15 ° C. for 10 hours and + 20 ° C. for 12 hours. After drying, the vial was filled with nitrogen gas and then sealed. The results of comparison of the properties of the freeze-dried sensitized hemocytes thus obtained are shown in Table 1. The appearance after drying was judged based on the degree of shrinkage. The reaction pattern is
2.5 ml of water was added to each lyophilized sensitized hemocyte to reconstitute a 1V / V% sensitized hemocyte suspension, and anti-thyroglobulin antibody-positive serum and negative serum were used as specimens and indirect carriers (hemocytes ) Judgment was made based on the positive and negative patterns when the agglutination reaction was performed. Those judged as x are those in which a positive negative pattern was observed. The reaction pattern was tested for its stability over time.
As a result, the samples evaluated as “good” in Table 1 have significantly improved storage stability.

実施例 2 実施例1で作製したサイログロブリン感作血球1V/V%
浮遊液に、第2表で示すような各々の安定剤を加えて、
以下実施例1と同様にして凍結乾燥し、作製した凍結乾
燥感作血球の性状を実施例1と同様にして比較した結果
を第2表に示す。第1表は安定剤を単味で用いたときの
効果を調べたものであり、第2表はアルブミンと糖を組
み合わせて添加したときの効果を調べたものである。
Example 2 Thyroglobulin-sensitized blood cells prepared in Example 1 1 V / V%
Add each stabilizer as shown in Table 2 to the suspension,
The results of lyophilization performed in the same manner as in Example 1 below and the properties of the lyophilized sensitized hemocytes thus produced were compared in the same manner as in Example 1 are shown in Table 2. Table 1 shows the effects when the stabilizer is used alone, and Table 2 shows the effects when the albumin and sugar are added in combination.

実施例 3 実施例1、実施例2の表1、表2の中で、著しく有効
であった安定剤サンプルNo.3、4、10、16、22、31、3
3、35、37、39、41の11サンプルについて、4℃で長期
間保存した後の凍結乾燥感作血球の力価を試験した結果
が第3表である。いずれのサンプルも4℃2年間安定で
あった。
Example 3 In Tables 1 and 2 of Example 1 and Example 2, stabilizer sample Nos. 3, 4, 10, 16, 22, 31, 3 which were remarkably effective.
Table 3 shows the results of testing the titer of freeze-dried sensitized blood cells after storing the 11 samples of 3, 35, 37, 39 and 41 for a long time at 4 ° C. All samples were stable at 4 ° C for 2 years.

実施例 4 実施例1、2で著しく有効であった保護剤11サンプル
について、凍結乾燥を行わないで液状のままの製品につ
いて実施例3と同様な保存安定性を調べた。結果は第4
表のとおりであり、6ヶ月〜1年の安定性を有してい
た。
Example 4 With respect to 11 samples of the protective agent which were remarkably effective in Examples 1 and 2, the same storage stability as in Example 3 was examined for the product in a liquid state without freeze-drying. The result is the fourth
As shown in the table, the stability was 6 months to 1 year.

実施例 5 サイログロブリン感作ラテックスについて実験した。Example 5 An experiment was conducted on thyroglobulin-sensitized latex.

ラテックスの感作方法は公知の方法(例えば、小田隆
弘 他:ラテックス凝集反応を用いたブドウ球菌エンテ
ロトキシンの食品等からの検出,福岡市衛試報,4,33−3
7,1979)に従った。すなわち、ラテッス(ポリスチレン
ラテックスSDL−59,武田薬品工業)をPBSで0.025W/V%
に希釈し、サイログロブリンPBS溶液25μg/mlを等量加
えて室温で1時間感作した。PBSで3回遠心洗浄したの
ち、PBSで浮遊させ、さらに窒化ソーダを0.1W/V%加え
0.025W/V%感作ラテックス浮遊液を作った。これに第5
表に示す安定剤を各々添加した浮遊液とし、そのまま液
状で保存した場合、あるいは実施例1と同様にして凍結
乾燥し、乾燥状態で保存した場合について、その保存安
定性を経時的に調べた。反応パターンに関する判定法は
実施例1に準じ、力価は感作ラテックス凝集反応マイク
ロタイター法の常法に従った。結果は第5表の通りであ
り、液状で6ヶ月〜1年の安定性を有し、乾燥状態で2
年以上の安定性を有していた。
A known method for sensitizing latex (for example, Takahiro Oda et al .: Detection of Staphylococcal Enterotoxin from Foods Using Latex Agglutination Reaction, Fukuoka Ichiei Test Report, 4, 33-3)
7, 1979). That is, latex (polystyrene latex SDL-59, Takeda Pharmaceutical Co., Ltd.) was used in PBS at 0.025 W / V%.
The mixture was diluted with 25 μg / ml of thyroglobulin PBS solution and sensitized at room temperature for 1 hour. After centrifuging and washing 3 times with PBS, suspend with PBS and add 0.1W / V% sodium nitride.
A 0.025 W / V% sensitized latex suspension was prepared. 5th to this
The storage stability was investigated with time when the suspensions shown in the table were added as suspensions and stored as a liquid as they were, or when freeze-dried in the same manner as in Example 1 and stored in a dry state. . The determination method for the reaction pattern was according to Example 1, and the titer was according to the conventional method of sensitized latex agglutination reaction microtiter method. The results are shown in Table 5, which is stable for 6 months to 1 year in liquid state and 2 in dry state.
It had been stable for more than a year.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】抗原または抗体感作担体の水性懸濁液から
なり、安定剤として5〜10W/V%のラクトースを含有
し、凍結乾燥してからなる免疫凝集反応用組成物。
1. A composition for immunoaggregation reaction, which comprises an aqueous suspension of an antigen- or antibody-sensitized carrier, contains 5-10 W / V% lactose as a stabilizer, and is freeze-dried.
【請求項2】安定剤として選択的に0.05〜1W/V%のアル
ブミンを含むことを特徴とする特許請求の範囲第(1)
項記載の組成物。
2. A stabilizer containing selectively 0.05 to 1 W / V% of albumin as a stabilizer.
The composition according to the item.
JP61052890A 1986-03-10 1986-03-10 Composition for immunoaggregation reaction Expired - Lifetime JPH0827283B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61052890A JPH0827283B2 (en) 1986-03-10 1986-03-10 Composition for immunoaggregation reaction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61052890A JPH0827283B2 (en) 1986-03-10 1986-03-10 Composition for immunoaggregation reaction

Publications (2)

Publication Number Publication Date
JPS62209362A JPS62209362A (en) 1987-09-14
JPH0827283B2 true JPH0827283B2 (en) 1996-03-21

Family

ID=12927458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61052890A Expired - Lifetime JPH0827283B2 (en) 1986-03-10 1986-03-10 Composition for immunoaggregation reaction

Country Status (1)

Country Link
JP (1) JPH0827283B2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3734015A1 (en) * 1987-10-08 1989-04-20 Behringwerke Ag DIAGNOSTIC AGENT AND METHOD FOR DETERMINING APOLIPOPROTEIN B
JPH021554A (en) * 1987-11-18 1990-01-05 Internatl Reagents Corp Reagent for deciding anti-d blood type
US5045446A (en) * 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
IL90188A0 (en) * 1988-05-18 1989-12-15 Cryopharm Corp Process and medium for the lyophilization of erythrocytes
JP2684425B2 (en) * 1989-09-06 1997-12-03 日本化薬株式会社 Latex reagent
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP7269906B2 (en) * 2019-10-29 2023-05-09 三洋化成工業株式会社 Immunoassay reagent, immunoassay kit, and immunoassay method
CN116840004A (en) * 2023-06-16 2023-10-03 武汉明德生物科技股份有限公司 Galectin 3 quality control product and preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003988A (en) * 1976-06-01 1977-01-18 Warner-Lambert Company Direct agglutination test for pregnancy

Also Published As

Publication number Publication date
JPS62209362A (en) 1987-09-14

Similar Documents

Publication Publication Date Title
Gitlin et al. Localization of C‐reactive protein in synovium of patients with rheumatoid arthritis
KR880001533B1 (en) Method for measuring antigen antibody response and its reagent
JPH11246593A (en) Protection of protein and its analogue
IE44471B1 (en) Stable preparation of erythrocytes process for preparing it and its use
US3564089A (en) Diagnostic reagent for syphilis
JPH0827283B2 (en) Composition for immunoaggregation reaction
EP0106495A2 (en) Method and reagent for detecting antivirus antibody
JPH10160734A (en) Calibration / control formulations for immunoassays
EP0000102A1 (en) Immunologic compositions, methods for preparing them and methods for conducting haemagglutination tests
US4096138A (en) Immunological test procedure
US5318913A (en) Reagent for the determination by hemagglutination of antibodies to bacterial toxins, method of preparation and application thereof
JPH0384461A (en) Immunological agglutination reagent and production thereof
CN111537326A (en) Method for preparing freeze-dried blood platelet and application thereof
JPH0322590B2 (en)
JPS5933227B2 (en) Reagents for serological reactions and their manufacturing method
US3925541A (en) Method of coating stabilized erythrocytes
Gupta et al. Use of formalinized sheep erythrocytes in the rubella hemagglutination-inhibition test
US4282002A (en) Sensitized sheep stroma immunoassay for rheumatoid factor
JP2584924B2 (en) Method for producing immunological agglutination particles
JP3040224B2 (en) Method for producing immunological agglutination particles
JP2505601B2 (en) Agglutination reagent
GB2163848A (en) Process for preserving fixed avian erythrocytes
JPH0230668B2 (en)
JPS6229746B2 (en)
JP3095478B2 (en) Method for producing immunological agglutination particles

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term